A newly published study shows Nevisense’s potential to differentiate the skin of children with AD from healthy skin – and suggest that EIS may have the ability to predict future AD development. The study was carried out by Caroline Roduit and her research group at CK Care.
Atopic Dermatitis is one of the most prevalent disorders in the world, affecting up to 20% of children globally. Currently, there is no clinical device that can assist in the diagnosis or severity assessment of AD. This study, performed on children between 4 months and 3 years of age, aimed at identifying children with Atopic Dermatitis with the use of Nevisense.
Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to create an Augmented Intelligence (AI) algorithm to identify healthy skin from atopic skin, even when measurements were performed on visually unaffected skin. In the study, Nevisense was also able to disregard certain potential artifacts in the dataset, such as age.
The authors concluded that EIS (Nevisense) can detect skin barrier dysfunction and differentiate skin of children with AD from healthy skin and suggests that EIS may have the ability to predict future AD development.
The full results of the study have now been published in the scientific journal Allergy and can be found here: https://onlinelibrary.wiley.com/doi/full/10.1111/all.15895.